EKSO BIONICS HOLDINGS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that EKSO BIONICS HOLDINGS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Mar 31, 2013 | $0 | Jul 3, 2013 |
| FY2012 | Mar 31, 2012 | $0 | Jul 3, 2013 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $2.45M | Mar 13, 2018 |
| FY2017 | Sep 30, 2017 | $1.60M | Mar 13, 2018 |
| FY2017 | Jun 30, 2017 | $1.87M | Mar 13, 2018 |
| FY2017 | Mar 31, 2017 | $1.44M | Mar 13, 2018 |
| FY2017 | Dec 31, 2016 | $2.59M | Mar 13, 2018 |
| FY2017 | Sep 30, 2016 | $1.60M | Mar 13, 2018 |
| FY2017 | Jun 30, 2016 | $1.55M | Mar 13, 2018 |
| FY2017 | Mar 31, 2016 | $8.49M | Mar 13, 2018 |
| FY2016 | Dec 31, 2015 | $1.94M | Mar 15, 2017 |
| FY2016 | Sep 30, 2015 | $2.92M | Mar 15, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.85M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $9.51M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $9.08M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $6.21M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $6.75M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $5.07M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $6.76M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $4.31M | Feb 27, 2020 |
| FY2017 | Dec 31, 2017 | $777.0K | Mar 13, 2018 |
| FY2017 | Sep 30, 2017 | $544.0K | Mar 13, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.70M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($11.33M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | ($15.20M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($15.08M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($9.76M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($15.83M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($12.13M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($26.99M) | Feb 27, 2020 |
| FY2017 | Dec 31, 2017 | ($8.98M) | Mar 13, 2018 |
| FY2017 | Sep 30, 2017 | ($6.34M) | Mar 13, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.33M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($10.46M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | ($15.11M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($15.56M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($13.83M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($13.29M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($16.64M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($27.03M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($31.61M) | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | ($27.59M) | Mar 13, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.03M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $3.87M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $5.03M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $3.63M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $2.55M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $2.47M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $4.60M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $5.85M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $9.48M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $8.88M | Mar 13, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Mar 31, 2013 | $1.4K | Jul 3, 2013 |
| FY2012 | Mar 31, 2012 | $157 | Jul 3, 2013 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.80M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($9.85M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | ($12.05M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($14.69M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($11.16M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($8.76M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($15.77M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($22.17M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($31.23M) | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | ($25.00M) | Mar 13, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $188.0K | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $37.0K | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $157.0K | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $194.0K | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $59.0K | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $60.0K | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $131.0K | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $456.0K | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $1.10M | Mar 13, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.11M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $26.65M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $28.92M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $40.90M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $49.17M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $20.60M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $21.92M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $17.66M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $37.99M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $24.43M | Mar 13, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.08M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $13.95M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $16.31M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $15.46M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $11.95M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $16.16M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $15.12M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $14.93M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $16.60M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $17.89M | Mar 13, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.03M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $12.71M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $12.61M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $25.44M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $37.22M | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | $4.43M | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | $6.80M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $2.73M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $21.39M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $6.53M | Feb 28, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $431.0K | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $431.0K | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $431.0K | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $431.0K | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 28, 2023 |
| FY2020 | Dec 31, 2020 | $0 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $189.0K | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $189.0K | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $189.0K | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $189.0K | Mar 13, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($262.40M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($250.48M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | ($239.15M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($223.95M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($208.87M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($199.10M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($183.28M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($171.15M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($144.15M) | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | ($114.86M) | Mar 13, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.17M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $4.49M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $8.64M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $20.53M | Mar 4, 2024 |
| FY2021 | Dec 31, 2021 | $40.41M | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | $12.86M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $10.87M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $7.66M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $27.81M | Feb 28, 2019 |
| FY2018 | Dec 31, 2016 | $16.85M | Feb 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $1.99M | Feb 24, 2022 |
| FY2020 | Dec 31, 2020 | $1.99M | Feb 25, 2021 |
| FY2019 | Dec 31, 2019 | $2.74M | Feb 27, 2020 |
| FY2018 | Dec 31, 2018 | $4.98M | Feb 28, 2019 |
| FY2017 | Dec 31, 2017 | $6.97M | Mar 13, 2018 |
| FY2016 | Dec 31, 2016 | $6.79M | Mar 15, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | (8) | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | (2) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 13, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | (8) | Feb 23, 2026 |
| FY2023 | Dec 31, 2023 | (1) | Mar 4, 2024 |
| FY2023 | Dec 31, 2022 | (1) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | (2) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 13, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.56M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | 1.48M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | 14.85M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 13.20M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | 12.69M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 8.35M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 5.80M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 62.96M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 59.94M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 21.89M | Mar 13, 2018 |